CompletedPhase 2NCT00571701

Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis

Studying Recurrent respiratory papillomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwell Health
Principal Investigator
Bettie M Steinberg, PhD
Long Island Jewish Medical Center
Intervention
celebrex (celecoxib)(drug)
Enrollment
50 target
Eligibility
2 years · All sexes
Timeline
20082015

Study locations (7)

Collaborators

National Institute on Deafness and Other Communication Disorders (NIDCD) · University of Iowa · Eastern Virginia Medical School · University of Alabama at Birmingham · University of California, San Francisco · Vanderbilt University · Sanford Health · Weill Medical College of Cornell University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00571701 on ClinicalTrials.gov

Other trials for Recurrent respiratory papillomatosis

Additional recruiting or active studies for the same condition.

See all trials for Recurrent respiratory papillomatosis

← Back to all trials